½ÃÀ庸°í¼­
»óǰÄÚµå
1639097

¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼®(Àç·áº°, ¾àÁ¦º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°) ¹× ¿¹Ãø(2022-2032³â)

Global Bioresorbable Coronary Stents Market Size Study, by Material (Polymer, Metal), Drug (Sirolimus, Novalimus), End Use (Outpatient, Inpatient Facilities), and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

2023³â ¼¼°è »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â ¾à 1¾ï 5,812¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È 4.10%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

»ýüÈí¼ö¼º Àç·á·Î ¸¸µé¾îÁø ÀÌ Çõ½ÅÀûÀÎ ½ºÅÙÆ®´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¿ëÇØµÇ¾î ¿µ±¸Àû ÀÓÇöõÆ®¿¡ µû¸¥ ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. °ü»óµ¿¸ÆÀÇ Á¤»óÀûÀÎ Ç÷·ù¸¦ º¹¿øÇϰí Àå±âÀûÀ¸·Î À̹°ÁúÀÇ Á¸À縦 Á¦°ÅÇÏ´Â ´É·ÂÀº ½ÉÇ÷°ü ÁßÀç¼ú¿¡¼­ ½ºÅÙÆ®ÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¼¼°èÀûÀ¸·Î ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. »ýüÈí¼ö¼º ½ºÅÙÆ®´Â Æú¸®¸Ó¿Í ±Ý¼Ó ±â¼úÀÇ ¹ßÀüÀ¸·Î ±âÁ¸ ½ºÅÙÆ®¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇϰí È¿°úÀûÀÎ ½ºÅÙÆ®¿¡ ´ëÇÑ ÀÓ»óÀû ¼ö¿ä¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ½Ç·Î¸®¹«½º ¹× ³ë¹Ù¸®¹«½º ¾à¹° ÄÚÆÃÀº ½ºÅÙÆ® »ðÀÔ ÈÄ ÀçÇùÂø ¹× ¿°ÁõÀ» ÃÖ¼ÒÈ­ÇÏ¿© ½ºÅÙÆ®ÀÇ ¼º´ÉÀ» ´õ¿í Çâ»ó½Ãŵ´Ï´Ù. ¿Ü·¡ Ä¡·á·ÎÀÇ ²ÙÁØÇÑ ÀüȯÀº ºñ¿ë È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¿ªÇÐÀ» °­È­ÇÏ´Â µ¥¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

³ôÀº ºñ¿ë°ú ±î´Ù·Î¿î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ̶ó´Â °úÁ¦°¡ ³²¾ÆÀÖÁö¸¸, ÀÌ·¯ÇÑ ¿ì·Á¸¦ ÇØ°áÇϱâ À§ÇÑ ¿¬±¸°³¹ßÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Àç·á°úÇÐÀÇ ¹ßÀü°ú Àå±âÀûÀÎ È¿°ú¿Í ¾ÈÀü¼ºÀ» ÀÔÁõÇÏ´Â ÀÓ»ó½ÃÇèÀ¸·Î ÀÎÇØ ÀÇ·áÁø°ú ȯÀڵ鿡°Ô ´õ ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ½ÃÀåÀº ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ¿Í ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® »ê¾÷¿¡ ¹Ì°³Ã´ÀÇ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, Çõ½Å¿¡ ´ëÇÑ ³ôÀº °ü½É, ³ôÀº ½ÉÇ÷°ü Áúȯ ¹ß»ý·ü·Î ÀÎÇØ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº Á¤ºÎÀÇ Áö¿ø Á¤Ã¥°ú Àß ±¸ÃàµÈ ½ÉÀå Ä¡·á ½Ã¼³¿¡ ÈûÀÔ¾î ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº °æÁ¦°¡ ºü¸£°Ô ¼ºÀåÇϰí ÷´Ü ÀÇ·á±â±â¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • Àç·áº°
      • Æú¸®¸Ó
      • ±Ý¼Ó
    • ¾àÁ¦º°
      • Sirolimus
      • Novalimus
    • ÃÖÁ¾ ¿ëµµº°
      • ¿Ü·¡ ȯÀÚ
      • ÀÔ¿ø ½Ã¼³
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦2Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : Á¤ÀÇ¹× ºÐ¼® ÀüÁ¦

  • ºÐ¼® ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • ºÐ¼® ÀüÁ¦
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ±¸Á¶
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ±¸Á¶
      • ±â¼ú Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • ºÐ¼® ¹æ¹ý
  • ºÐ¼® ´ë»ó ±â°£
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨¿¡ÀÇ ÇâÈÄ Á¢±Ù
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æÀû
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû º¯È­ µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦5Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Àç·áº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, Àç·áº°(2022³â/2032³â)
    • Æú¸®¸Ó
    • ±Ý¼Ó

Á¦6Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¾àÁ¦º°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, ¾àÁ¦º°(2022³â/2032³â)
    • Sirolimus
    • Novalimus

Á¦7Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2022³â/2032³â)
    • ¿Ü·¡ ȯÀÚ
    • ÀÔ¿ø ½Ã¼³

Á¦8Àå ¼¼°èÀÇ »ýüÈí¼ö¼º °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic Plc
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Abbott Laboratories
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Boston Scientific Corporation
    • Medtronic Plc
    • Terumo Corporation
    • Biotronik SE & Co. KG
    • Meril Life Sciences Pvt. Ltd.
    • Elixir Medical Corporation
    • OrbusNeich
    • Lepu Medical Technology(Beijing) Co., Ltd.
    • Amaranth Medical, Inc.

Á¦10Àå ºÐ¼® ÇÁ·Î¼¼½º

  • ºÐ¼® ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ¿¹Ãø
    • °ËÁõ
    • ÃâÆÇ
  • ºÐ¼® ¼Ó¼º
LSH 25.02.27

The Global Bioresorbable Coronary Stents Market, valued at approximately USD 158.12 million in 2023, is poised to grow steadily at a CAGR of 4.10% over the forecast period 2024-2032. These innovative stents, made from bioresorbable materials, dissolve over time, reducing complications associated with permanent implants. Their capacity to restore normal blood flow in coronary arteries while eliminating the long-term presence of foreign materials underscores their importance in cardiovascular interventions.

The market's expansion is fueled by increasing prevalence of cardiovascular diseases globally and a growing preference for minimally invasive treatments. Bioresorbable stents, with advancements in polymer and metal technologies, are meeting the clinical demand for safer, more effective alternatives to conventional stents. Sirolimus and Novalimus drug coatings further enhance stent performance by minimizing restenosis and inflammation post-implantation. The steady shift toward outpatient facilities for procedures is also bolstering market dynamics by offering cost-effective and patient-friendly solutions.

While high costs and stringent regulatory approvals remain challenges, significant research and development efforts are underway to address these concerns. Advancements in material science and clinical trials demonstrating long-term efficacy and safety are driving broader acceptance among healthcare professionals and patients. Emerging markets in Asia-Pacific and Latin America, with rising healthcare investments and awareness, represent untapped opportunities for the bioresorbable coronary stents industry.

Regionally, North America dominates the market owing to its advanced healthcare infrastructure, strong focus on innovation, and high incidence of cardiovascular diseases. Europe closely follows, driven by supportive government policies and well-established cardiac care facilities. The Asia-Pacific region, with its burgeoning economies and increasing focus on advanced medical devices, is expected to exhibit the fastest growth over the forecast period.

Major market players included in this report are:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic Plc
  • Terumo Corporation
  • Biotronik SE & Co. KG
  • Meril Life Sciences Pvt. Ltd.
  • Elixir Medical Corporation
  • OrbusNeich
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Amaranth Medical, Inc.
  • Reva Medical, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • C.R. Bard, Inc.
  • Stentys SA
  • SMT (Sahajanand Medical Technologies)

The detailed segments and sub-segment of the market are explained below:

By Material:

  • Polymer
  • Metal

By Drug:

  • Sirolimus
  • Novalimus

By End Use:

  • Outpatient
  • Inpatient Facilities

By Region:

North America:

  • U.S.
  • Canada

Europe:

  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific:

  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America:

  • Brazil
  • Mexico

Middle East & Africa:

  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Key Takeaways:

  • Market estimates and forecasts spanning 2022-2032.
  • Annualized revenues with detailed regional and segment analysis.
  • Insights into critical market drivers, challenges, and opportunities.
  • Profiles of leading market players and analysis of key strategies.
  • Regional and global trends shaping the future of bioresorbable coronary stents.

Table of Contents

Chapter 1. Global Bioresorbable Coronary Stents Market Executive Summary

  • 1.1. Global Bioresorbable Coronary Stents Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Material
      • 1.3.1.1. Polymer
      • 1.3.1.2. Metal
    • 1.3.2. By Drug
      • 1.3.2.1. Sirolimus
      • 1.3.2.2. Novalimus
    • 1.3.3. By End Use
      • 1.3.3.1. Outpatient
      • 1.3.3.2. Inpatient Facilities
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Bioresorbable Coronary Stents Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Bioresorbable Coronary Stents Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increasing Prevalence of Cardiovascular Diseases
    • 3.1.2. Growing Preference for Minimally Invasive Treatments
    • 3.1.3. Advancements in Material and Drug Technologies
  • 3.2. Market Challenges
    • 3.2.1. High Costs Associated with Bioresorbable Stents
    • 3.2.2. Stringent Regulatory Approvals
  • 3.3. Market Opportunities
    • 3.3.1. Innovations in Device Design
    • 3.3.2. Increasing Demand in Pediatric Care
    • 3.3.3. Regional Investments in Healthcare Infrastructure

Chapter 4. Global Bioresorbable Coronary Stents Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunities
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Bioresorbable Coronary Stents Market Size & Forecasts by Material 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Bioresorbable Coronary Stents Market: Material Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
    • 5.2.1. Polymer
    • 5.2.2. Metal

Chapter 6. Global Bioresorbable Coronary Stents Market Size & Forecasts by Drug 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Bioresorbable Coronary Stents Market: Drug Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
    • 6.2.1. Sirolimus
    • 6.2.2. Novalimus

Chapter 7. Global Bioresorbable Coronary Stents Market Size & Forecasts by End Use 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Bioresorbable Coronary Stents Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
    • 7.2.1. Outpatient
    • 7.2.2. Inpatient Facilities

Chapter 8. Global Bioresorbable Coronary Stents Market Size & Forecasts by Region 2022-2032

  • 8.1. North America Bioresorbable Coronary Stents Market
    • 8.1.1. U.S. Bioresorbable Coronary Stents Market
      • 8.1.1.1. Application Breakdown Size & Forecasts, 2022-2032
      • 8.1.1.2. Patient Breakdown Size & Forecasts, 2022-2032
      • 8.1.1.3. End Use Breakdown Size & Forecasts, 2022-2032
    • 8.1.2. Canada Bioresorbable Coronary Stents Market
  • 8.2. Europe Bioresorbable Coronary Stents Market
    • 8.2.1. UK Bioresorbable Coronary Stents Market
    • 8.2.2. Germany Bioresorbable Coronary Stents Market
    • 8.2.3. France Bioresorbable Coronary Stents Market
    • 8.2.4. Spain Bioresorbable Coronary Stents Market
    • 8.2.5. Italy Bioresorbable Coronary Stents Market
    • 8.2.6. Rest of Europe Bioresorbable Coronary Stents Market
  • 8.3. Asia-Pacific Bioresorbable Coronary Stents Market
    • 8.3.1. China Bioresorbable Coronary Stents Market
    • 8.3.2. India Bioresorbable Coronary Stents Market
    • 8.3.3. Japan Bioresorbable Coronary Stents Market
    • 8.3.4. Australia Bioresorbable Coronary Stents Market
    • 8.3.5. South Korea Bioresorbable Coronary Stents Market
    • 8.3.6. Rest of Asia Pacific Bioresorbable Coronary Stents Market
  • 8.4. Latin America Bioresorbable Coronary Stents Market
    • 8.4.1. Brazil Bioresorbable Coronary Stents Market
    • 8.4.2. Mexico Bioresorbable Coronary Stents Market
    • 8.4.3. Rest of Latin America Bioresorbable Coronary Stents Market
  • 8.5. Middle East & Africa Bioresorbable Coronary Stents Market
    • 8.5.1. Saudi Arabia Bioresorbable Coronary Stents Market
    • 8.5.2. South Africa Bioresorbable Coronary Stents Market
    • 8.5.3. Rest of Middle East & Africa Bioresorbable Coronary Stents Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Abbott Laboratories
    • 9.1.2. Boston Scientific Corporation
    • 9.1.3. Medtronic Plc
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Abbott Laboratories
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Market Strategies
    • 9.3.2. Boston Scientific Corporation
    • 9.3.3. Medtronic Plc
    • 9.3.4. Terumo Corporation
    • 9.3.5. Biotronik SE & Co. KG
    • 9.3.6. Meril Life Sciences Pvt. Ltd.
    • 9.3.7. Elixir Medical Corporation
    • 9.3.8. OrbusNeich
    • 9.3.9. Lepu Medical Technology (Beijing) Co., Ltd.
    • 9.3.10. Amaranth Medical, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦